← Russell 3000 cross-section

RYTM RHYTHM PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$7.7bn
Revenue TTM
$240m
Net income TTM
$-205m
Free cash flow
Composite score
Sector rank
#842

Valuation

P / E
EV / EBITDA
EV / sales
31.0
FCF yield
Earnings yield vs 10-yr
-7.41pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-85.6%
EBITDA margin
ROE
-199.4%
ROIC
Revenue growth
53.5%

Insider activity, last 90 days

Net open-market
$-20.75m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

While obesity affects hundreds of millions of people worldwide, we are advancing therapies for a subset of individuals who have hyperphagia, a pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, decreased energy expenditure and severe obesity due to diseases such as acquired or congenital hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS) or other diseases caused by impaired MC4R pathway signaling. Additional recent clinical, regulatory, corporate and commercial updates include: • On Aug. …RHYTHM PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →